| 产品名称： | MY904 904 |
|---|---|
| 商品货号： | TS211411 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Leukemia |
| Strain： | Strain:xa0 BALB/c (B cell); BALB/c (myeloma) |
| Applications： | The antibody reacts with granulocytes, monocytes and a subset of large granular lymphocytes. The antibody can be used to reduce the inflammatory response of leukocytes in vivo. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human inflammatory cells (phagocytic leukocytes); against CD11b |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human inflammatory cells (phagocytic leukocytes); against CD11b |
| Comments： | Animals were immunized with human chronic granulocytic leukemia (CGL) cells. Spleen cells were fused with NS-1 myeloma cells. The antibody reacts with granulocytes, monocytes and a subset of large granular lymphocytes. It inhibits adhesion related functions, but does not block iC3b binding. The antibody can be used to reduce the inflammatory response of leukocytes in vivo. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Iscoves Modified Dulbeccos Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG1 |
| Name of Depositor： | Univ. Michigan, Dana Farber Cancer Inst. |
| U.S. Patent Number： | |
| References： | Lucchesi BR, et al. Method of reducing tissue damage at an inflammatory site using a monoclonal antibody. US Patent 4,840,793 dated Jun 20 1989 Dana N, et al. Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J. Immunol. 137: 3259-3263, 1986. PubMed: 2430017 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | MY904 904 |
|---|---|
| 商品货号： | TS211411 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Leukemia |
| Strain： | Strain:xa0 BALB/c (B cell); BALB/c (myeloma) |
| Applications： | The antibody reacts with granulocytes, monocytes and a subset of large granular lymphocytes. The antibody can be used to reduce the inflammatory response of leukocytes in vivo. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human inflammatory cells (phagocytic leukocytes); against CD11b |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human inflammatory cells (phagocytic leukocytes); against CD11b |
| Comments： | Animals were immunized with human chronic granulocytic leukemia (CGL) cells. Spleen cells were fused with NS-1 myeloma cells. The antibody reacts with granulocytes, monocytes and a subset of large granular lymphocytes. It inhibits adhesion related functions, but does not block iC3b binding. The antibody can be used to reduce the inflammatory response of leukocytes in vivo. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Iscoves Modified Dulbeccos Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG1 |
| Name of Depositor： | Univ. Michigan, Dana Farber Cancer Inst. |
| U.S. Patent Number： | |
| References： | Lucchesi BR, et al. Method of reducing tissue damage at an inflammatory site using a monoclonal antibody. US Patent 4,840,793 dated Jun 20 1989 Dana N, et al. Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J. Immunol. 137: 3259-3263, 1986. PubMed: 2430017 |
